2001
Effect of Opioid Dependence Pharmacotherapies on Zidovudine Disposition
McCance‐Katz E, Rainey P, Friedland G, Kosten T, Jatlow P. Effect of Opioid Dependence Pharmacotherapies on Zidovudine Disposition. American Journal On Addictions 2001, 10: 296-307. PMID: 11783744, DOI: 10.1111/j.1521-0391.2001.tb00519.x.Peer-Reviewed Original ResearchConceptsOpioid-dependence pharmacotherapyHuman immunodeficiency virusZDV toxicityActive antiretroviral therapyInjection drug usersTime-concentration curveZDV pharmacokineticsZidovudine dispositionAntiretroviral therapyOpioid pharmacotherapyDose adjustmentOpioid dependenceImmunodeficiency virusZDV concentrationsControl subjectsMethadone maintenanceDrug usersPharmacotherapyZidovudineBuprenorphineNaltrexoneSignificant differencesLAAMToxicitySubjects
2000
In Vivo Antagonism with Zidovudine plus Stavudine Combination Therapy
Havlir D, Tierney C, Friedland G, Pollard R, Smeaton L, Sommadossi J, Fox L, Kessler H, Fife K, Richman D. In Vivo Antagonism with Zidovudine plus Stavudine Combination Therapy. The Journal Of Infectious Diseases 2000, 182: 321-325. PMID: 10882616, DOI: 10.1086/315683.Peer-Reviewed Original ResearchConceptsCD4 cell countD4TCell countD4T armD4T monotherapyWeeks of therapyHuman immunodeficiency virusCopies/mLGreater antiviral activityT monotherapyHIV RNACurrent regimenImmunodeficiency virusPharmacologic antagonismCombination therapyMean reductionZidovudineAntiviral activityVivo antagonismProgressive declinePatientsCells/DdIIntracellular levelsTherapy
1999
Efficacy and Safety of Delavirdine Mesylate With Zidovudine and Didanosine Compared With Two-Drug Combinations of These Agents in Persons With HIV Disease With CD4 Counts of 100 to 500 cells/mm3 (ACTG 261)
Friedland G, Pollard R, Griffith B, Hughes M, Morse G, Bassett R, Freimuth W, Demeter L, Connick E, Nevin T, Hirsch M, Fischl M. Efficacy and Safety of Delavirdine Mesylate With Zidovudine and Didanosine Compared With Two-Drug Combinations of These Agents in Persons With HIV Disease With CD4 Counts of 100 to 500 cells/mm3 (ACTG 261). JAIDS Journal Of Acquired Immune Deficiency Syndromes 1999, 21: 281-292. PMID: 10428106, DOI: 10.1097/00126334-199908010-00005.Peer-Reviewed Original ResearchConceptsCells/mm3CD4 cell countTwo-drug combinationsCell countHIV-1 RNA changesHIV-1 RNA levelsMonths of monotherapyThree-drug regimenTwo-drug armTwo-drug regimensGastrointestinal side effectsThree-drug combinationDelavirdine mesylateNon-nucleoside reverseCD4 countCD4 cellsHIV diseaseKey efficacyMulticenter trialCopies/Antiretroviral activityHIV-1Side effectsDidanosineZidovudine
1992
Pharmacokinetic interactions of zidovudine and methadone in intravenous drug-using patients with HIV infection.
Schwartz E, Brechbühl A, Kahl P, Miller M, Selwyn P, Friedland G. Pharmacokinetic interactions of zidovudine and methadone in intravenous drug-using patients with HIV infection. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1992, 5: 619-26. PMID: 1588496.Peer-Reviewed Original ResearchConceptsIntravenous drug usersControl patientsMethadone patientsPharmacokinetic parametersHigh-pressure liquid chromatographyFormer intravenous drug usersIntravenous drug-using patientsMethadone maintenance therapyDrug-using patientsConcentration-time curveHuman hepatic microsomesZDV levelsZDV therapyZDV treatmentMaintenance therapyMethadone concentrationsMethadone groupHIV infectionPharmacokinetic interactionsSerum levelsConcurrent administrationIVDU patientsUrinary excretionPatientsZidovudine